ストックスクリーナーアプリを入手
2.95
0.34%
0.01
アフターアワーズ：
2.98
0.03
+1.02%
前日終値:
$2.94
開ける：
$2.9
24時間の取引高:
89,045
Relative Volume:
1.98
時価総額：
$30.63M
収益：
-
当期純損益:
$-19.09M
株価収益率:
-2.2325
EPS:
-1.3214
ネットキャッシュフロー:
$-17.24M
1週間 パフォーマンス:
-15.47%
1か月 パフォーマンス:
-12.20%
6か月 パフォーマンス:
-53.03%
1年 パフォーマンス:
-25.88%
1日の値動き範囲:
$2.79
$2.98
1週間の範囲:
$2.79
$3.5737
52週間の値動き範囲:
$2.79
$11.99
Lantern Pharma Inc Stock (LTRN) Company Profile
LTRN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| LTRN | 2.95 | 30.63M | 0 | -19.09M | -17.24M | -1.3214 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-07 | 開始されました | H.C. Wainwright | Buy |
Lantern Pharma Inc (LTRN) 最新ニュース
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call Transcript - MSN
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - BioSpace
Lantern Pharma stock hits 52-week low at $3.0 amid market challenges - Investing.com
32BJ Health Fund Selects Lantern as Surgery Network Partner - GlobeNewswire Inc.
LTRN: Pediatric Rare Cancer in Focus - Yahoo Finance
Earnings call: Lantern Pharma reports Q3 2024 financials and trial updates - Investing.com India
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... By GuruFocus - Investing.com Canada
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Stra - GuruFocus.com
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... - Yahoo Finance
Lantern Pharma Advances AI-Driven Cancer Therapies - TipRanks
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates - BioSpace
Starlight Therapeutics Assembles Elite Brain Cancer Advisory Board, Backed by Top Oncologists | LTRN Stock News - StockTitan
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Simply Wall St
Non-Smokers Keep Getting Lung Cancer. Dallas’ Lantern Pharma Is Using AI to Fight Back - D Magazine
Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET - BioSpace
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - ForexTV.com
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 - Business Wire
Lantern Pharma to Host & Participate in Two Public Webinars During October - Business Wire
FDA grants Fast Track Designation to LP-184 for GBM treatment - Investing.com Canada
Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA - BioSpace
FDA Grants Fast Track Designation to LP-184 for Glioblastoma - OncLive
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Prom - GuruFocus.com
After-Hour Surge: Lantern Pharma (LTRN) Shares Climb On Regulatory Approvals - Stocks Telegraph
11 Best AI Penny Stocks Under $10 in 2024 - CoinCodex
Lantern Pharma secures three new FDA rare disease tags - Investing.com
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers - BioSpace
Lantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184 - MarketWatch
Norton Cancer Institute patient receives first-in-world clinical trial medicine dose - Norton Healthcare
Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire - Yahoo Finance
NDA Submitted to FDA for TLX101-CDx in Progressive/Recurrent Glioma - OncLive
11 Penny Stocks That Will Make You A Millionaire - Insider Monkey
LTRN (Lantern Pharma) EPS (Basic) : $-1.65 (TTM As of Jun. 2024) - GuruFocus.com
The Targeted Pulse: Apalutamide Provides a Faster, Deeper PSA Response vs Enzalutamide, Vorasidenib Receives Approval in Glioma, and More - Targeted Oncology
Lantern Pharma Inc. (NASDAQ:LTRN) Short Interest Update - Defense World
LTRN (Lantern Pharma) 50-Day SMA : $4.42 (As of Aug. 17, 2024) - GuruFocus.com
LTRN (Lantern Pharma) EV-to-Revenue : (As of Aug. 16, 2024) - GuruFocus.com
Q3 2024 Earnings Forecast for Lantern Pharma Inc. (NASDAQ:LTRN) Issued By Zacks Small Cap - Defense World
LTRN: Second Quarter Results - Yahoo Finance
The Targeted Pulse: The Practice-Changing Approval of Afami-cel for Advanced Synovial Sarcoma, Buprenorphine Offers Pain Relief for Bone Marrow Transplant, and More - Targeted Oncology
Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript - Seeking Alpha
LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024 - MSN
Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates - StockTitan
Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 - Business Wire
Lantern Pharma (LTRN) Scheduled to Post Quarterly Earnings on Thursday - Defense World
LTRN: Harmonic Clinical Update - Zacks Small Cap Research
Lantern Pharma Inc (LTRN) 財務データ
収益
当期純利益
現金流量
EPS
Lantern Pharma Inc (LTRN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Fletcher Aaron G.L. | 10% Owner |
May 23 '24 |
Sale |
6.25 |
10,000 |
62,500 |
59,326 |
| Fletcher Aaron G.L. | 10% Owner |
Feb 28 '24 |
Sale |
4.85 |
74,297 |
360,340 |
62,088 |
| Fletcher Aaron G.L. | 10% Owner |
Feb 27 '24 |
Sale |
4.40 |
50,000 |
220,000 |
68,997 |
| Fletcher Aaron G.L. | 10% Owner |
Feb 29 '24 |
Sale |
4.87 |
19,703 |
95,954 |
60,256 |
| Kreis Leslie W. | 10% Owner |
Feb 28 '24 |
Sale |
4.85 |
74,297 |
360,340 |
62,088 |
| Kreis Leslie W. | 10% Owner |
Feb 27 '24 |
Sale |
4.40 |
50,000 |
220,000 |
68,997 |
| Kreis Leslie W. | 10% Owner |
Feb 29 '24 |
Sale |
4.87 |
19,703 |
95,954 |
60,256 |
| Fletcher Aaron G.L. | 10% Owner |
Jan 17 '24 |
Sale |
4.20 |
58,889 |
247,334 |
73,646 |
| Kreis Leslie W. | 10% Owner |
Jan 17 '24 |
Sale |
4.20 |
58,889 |
247,334 |
73,646 |
| Fletcher Aaron G.L. | 10% Owner |
Nov 29 '23 |
Sale |
3.44 |
145,348 |
499,997 |
217,553 |
0.93%
3.55%
大文字化:
|
ボリューム (24 時間):